The molecular basis of sarcoma remains poorly understood. However, recent 
studies have begun to uncover some of the molecular pathways involved in 
sarcomagenesis. The chemokine receptor CXCR4 has been implicated in sarcoma 
development and has been found to be a prognostic marker for poor clinical 
outcome. There is growing evidence that overexpression of CXCR4 plays a 
significant role in development of metastatic disease, especially in directing 
tumor cells towards the preferential sites of metastases in sarcoma, lung and 
bone. Although further investigation is necessary to validate these pathways, 
there is potential for clinical application, particularly in the use of 
pharmacologic inhibitors of CXCR4 as means of preventing sarcoma metastasis.